A clinical variable‐based nomogram could predict the survival for advanced NSCLC patients receiving second‐line atezolizumab
Abstract Objective A nomogram model based on clinical variables was conducted to predict the survival in patients with non‐small cell lung cancer (NSCLC) receiving second‐line atezolizumab. Methods Four hundred and twenty‐four patients with NSCLC receiving atezolizumab from OAK study were regarded a...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-09-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.4160 |